Alejandro Lopez Neyra

Dr. Alejandro Lopez Neyra

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
AGAntonio Nieto García
Antonio Nieto García
TGTeresa Garriga-Baraut
Teresa Garriga-Baraut
AMAna Mª Plaza Martín
Ana Mª Plaza Martín
MCMaría Nieto Cid
María Nieto Cid
JTJavier Torres-Borrego
Javier Torres-Borrego
AMAngel Mazon
Angel Mazon

1 November 2020 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
ANAlejandro Lopez Neyra
Alejandro Lopez Neyra
LSLucrecia Suárez
Lucrecia Suárez
MMMarta Muñoz
Marta Muñoz
ABAna de Blas
Ana de Blas
MVMarta Ruiz de Valbuena
Marta Ruiz de Valbuena
ALAdelaida Lamas
Adelaida Lamas

29 April 2009 in Cases Journal
Verified
Journal Article
Open access
SVSergio Vano-Galvan
Sergio Vano-Galvan
DMDong-Lai Ma
Dong-Lai Ma
ANAlejandro Lopez Neyra
Alejandro Lopez Neyra
BPBibiana Perez
Bibiana Perez
EMErnesto Muñoz-Zato
Ernesto Muñoz-Zato
PJPedro Jaén
Pedro Jaén
Pityriasis rosea is a self-limited inflammatory condition of the skin that mostly affects healthy children and adolescents. Atypical cases of Pityriasis rosea are fairly common and less readily recognized than typical eruptions, and may pose a diagnostic challenge. We report the case of a 12-year-old black child that developed an intense pruritic papular eruption with intense facial involvement that was diagnosed of Pityriasis rosea and resolved after five weeks leaving a slight hyperpigmentation. Facial and scalp involvement, post-inflammatory disorders of pigmentation and papular lesions are characteristics typically associated to black patients with Pityriasis rosea. The knowledge of features found more frequently in dark-skinned population may be helpful to physicians for diagnosing an atypical Pityriasis rosea in these patients.

1 March 2013 in Anales de Pediatría
Verified
Journal Article
Closed access
VSV. Sanz Santiago
V. Sanz Santiago
ANAlejandro Lopez Neyra
Alejandro Lopez Neyra
EGE. Almería Gil
E. Almería Gil
JAJ.R. Villa Asensi
J.R. Villa Asensi

8 April 2023 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
MNMaría Nieto‐Cid
María Nieto‐Cid
TGTeresa Garriga-Baraut
Teresa Garriga-Baraut
APAna Mª. Plaza‐Martín
Ana Mª. Plaza‐Martín
MTMiguel Tortajada-Girbés
Miguel Tortajada-Girbés
JTJavier Torres-Borrego
Javier Torres-Borrego
ANAntonio Nieto‐García
Antonio Nieto‐García

3 July 2025 in Children
Verified
Journal Article
Open access
PDF file
Guillermo García-Pérez-de-SevillaGuillermo García-Pérez-de-Sevilla
Guillermo García-Pérez-de-Sevilla
ÁBÁngela Blanco-Velasco
Ángela Blanco-Velasco
TYThomas Yvert
Thomas Yvert
VSVerónica Sanz-Santiago
Verónica Sanz-Santiago
ATAna Morales Tirado
Ana Morales Tirado
MRMargarita Perez Ruiz
Margarita Perez Ruiz
Objective: The objective of this study was to analyze respiratory muscle function in children and adolescents with cystic fibrosis (CF) treated with Elexacaftor/Tezacaftor/Ivacaftor (ETI) compared to healthy individuals, based on the hypothesis that CFTR modulators may improve respiratory muscle strength. Methods: A descriptive, observational, cross-sectional study was conducted with patients with CF treated with ETI aged 6–18 years. Lung function, maximal expiratory and inspiratory pressures (MIP and MEP), diet quality (KIDMED), and physical activity levels (PAQ) were assessed. The student’s t-test or the Mann–Whitney U-test was used to compare differences between groups. The effect size was calculated with Cohen’s d. Significance level was set as a p-value < 0.05. Results: A total of 48 children and adolescents (60.4% male) were analyzed in this study (24 healthy and 24 with CF). The participants with CF had mild pulmonary involvement. No significant differences were found in respiratory muscle strength between groups (MEPmax p = 0.440, MIPmax p = 0.206). Patients with CF showed lower KIDMED (p = 0.022) and PAQ (p = 0.010) scores. However, the MIP and MEP values observed in CF participants were higher than those reported in previous studies conducted before the introduction of ETI modulators. Conclusions: Children and adolescents with CF treated with ETI showed respiratory muscle strength comparable to that of healthy controls. Despite differences in lifestyle factors, these findings may reflect a positive impact of CFTR modulators on respiratory muscle function, although further longitudinal and controlled studies are needed.